Evidence map›Paper›PMID 41826982›Full record

ArticleMolecular cancer2026

Targeting MYC in T-Cell lymphoma via epigenetic modulation with a small-molecule inhibitor.

Bangdong Liu, Bowen Jiang, Shihua Liu, Shihao Zhang, Zhijian Huang, Min Zhang, Xianlan Zhao, Qiong Li, Xinlei Li, Jing Xia and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bangdong Liu *Medical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Bowen Jiang *Medical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Shihua LiuCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Shihao ZhangDepartment of Immunology, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Zhijian HuangDepartment of Basic Medicine, Chongqing Medical University, Chongqing, China.
Min ZhangMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Xianlan ZhaoMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Qiong LiMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Xinlei LiMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Jing XiaMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Dezhi HuangMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Huan LiMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Xiaoqing LuoMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Naya MaMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Yadan HuMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China.
Xi ZhangMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China. zhangxi@tmmu.edu.cn.
Jun RaoMedical Center of Hematology, Xinqiao Hospital, Army Medical University, 183 Xinqiao Main Street, Chongqing, 400037, China. raojun1129@126.com.

Funding

National Natural Science Foundation of China 82470191National Natural Science Foundation of China 82500252
6 · The paper itself

Abstract

T-cell lymphoma (TCL) represents a heterogeneous group of highly aggressive malignancies with poor clinical outcomes because of limited therapeutic options. Hence, targeted therapeutic strategies for TCL are urgently needed. Up-regulation of MYC is observed in more than 90% of all patients with TCL and correlates with tumor progression. Thus, targeting MYC may be an attractive therapeutic strategy for TCL. Here, we identified Lanatoside C (LATC) as a potent anti-TCL agent through unbiased high-throughput screening using an FDA-approved drug library. LATC inhibited cell proliferation and invasiveness of TCL in both the tumor-bearing mice and preclinical PDX models. Mechanistically, LATC disturbed the interaction between m5C reader YBX1 and m5C-modified MYC mRNA to reduce MYC mRNA stability through binding and blocking the RNA recognition domain of YBX1. Meanwhile, LATC directly targeted oncogenic p300 to enhance its proteasomal degradation through repressing UCHL3-mediated p300 deubiquitylation, which consequently down-regulated H4K16 lactylation in the MYC promoter to inhibit its transcription. Taken together, we identified LATC as an epigenetic agent by dually targeting post-transcriptional YBX1/MYC mRNA stability and transcriptional p300/H4K16 lactylation to inhibit MYC-driven T-cell lymphoma progression, providing a novel targeted therapeutic strategy for patients with MYC overexpression.

Indexed as

Antineoplastic AgentsEpigenesis, GeneticLymphoma, T-CellProto-Oncogene Proteins c-mycSmall Molecule LibrariesAnimalsCell Line, TumorCell ProliferationE1A-Associated p300 ProteinGene Expression Regulation, NeoplasticHumansMicePromoter Regions, GeneticXenograft Model Antitumor AssaysY-Box-Binding Protein 1Antineoplastic AgentsE1A-Associated p300 ProteinProto-Oncogene Proteins c-mycSmall Molecule LibrariesY-Box-Binding Protein 1YBX1 protein, humanLactylationLanatoside Cm5CMYCp300T-cell lymphomaYBX1

Identifiers

PMID41826982
PMCPMC13097743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.